Jared Moskowitz
Trade Performance Intelligence
Score: 0/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
5 flagsJared Moskowitz bought $15,001 - $50,000 in $GS (Goldman Sachs Group, Inc.) on 2025-10-10, 25 days before the Merchant Banking Modernization Act (HR5291) was introduced, a bill that could benefit financial holding companies.
Jared Moskowitz sold $1,001 - $15,000 in $JNJ (Johnson & Johnson Common Stock) on 2025-10-10, 41 days before the Lowering Drug Costs for American Families Act (HR6166) was introduced, a bill that could impact pharmaceutical company revenues.
Jared Moskowitz bought $1,001 - $15,000 in $MCK (McKesson Corporation Common Stock) on 2025-10-10, 41 days before the Baby Bonus Act (HR6234) was introduced, which could increase disposable income for families.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $AXP | American Express Company Common Stock (AXP) [ST] | $15K-$50K | — | — | — | Oct 10, 2025 |
| BUY | $AVGO | Broadcom Inc. - Common Stock (AVGO) [ST] | $15K-$50K | — | — | — | Oct 10, 2025 |
| BUY | $CSCO | Cisco Systems, Inc. - Common Stock (CSCO) [ST] | $15K-$50K | — | — | — | Oct 10, 2025 |
| BUY | $DELL | Dell Technologies Inc. Class C Common Stock (DELL) [ST] | $15K-$50K | — | — | — | Oct 10, 2025 |
| BUY | $GS | Goldman Sachs Group, Inc. (GS) [ST] | $15K-$50K | — | — | — | Oct 10, 2025 |
| BUY | $AXP | American Express Company Common Stock (AXP) [ST] | $1K-$15K | — | — | — | Oct 10, 2025 |
| BUY | $AXP | American Express Company Common Stock (AXP) [ST] | $1K-$15K | — | — | — | Oct 10, 2025 |
| BUY | $AVGO | Broadcom Inc. - Common Stock (AVGO) [ST] | $1K-$15K | — | — | — | Oct 10, 2025 |
| BUY | $AVGO | Broadcom Inc. - Common Stock (AVGO) [ST] | $1K-$15K | — | — | — | Oct 10, 2025 |
| BUY | $CSCO | Cisco Systems, Inc. - Common Stock (CSCO) [ST] | $1K-$15K | — | — | — | Oct 10, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Lowering Drug Costs for American Families Act
The Lowering Drug Costs for American Families Act directly reduces pharmaceutical company revenues by expanding federal drug price negotiation and extending Medicare inflation rebates to commercial markets. This legislation mandates significant revenue contraction for drug manufacturers and increases cost management pressure on health insurers due to new out-of-pocket limits. Pharmaceutical stocks will decline, while health insurer margins will tighten.
Skinny Labels, Big Savings Act
The 'Skinny Labels, Big Savings Act' (HR6485) aims to reduce patent infringement risk for generic drug manufacturers by providing a statutory safe harbor, directly reversing the GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. precedent. This bill, currently in the early stages of the legislative process, would increase market access for generics and biosimilars, benefiting companies like Teva Pharmaceutical Industries Limited ($TEVA) and Viatris Inc. ($VTRS), while potentially increasing competition for innovator drug companies such as Amgen Inc. ($AMGN), Pfizer Inc. ($PFE), Johnson & Johnson ($JNJ), and Merck & Co., Inc. ($MRK).
Baby Bonus Act
The 'Baby Bonus Act' establishes direct payments to parents starting January 1, 2026, increasing disposable income for families with children. This directly benefits consumer goods companies focused on infant and child products and pediatric healthcare providers. The bill creates a new federal program, ensuring a sustained revenue stream for affected industries.
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.
HR5917 authorizes the President to grant normal trade relations (NTR) status to most countries, excluding Belarus, Cuba, and North Korea, by waiving the Jackson-Vanik amendment. This action reduces tariffs and trade barriers for goods from these countries, directly benefiting U.S. importers and consumers through lower costs. Companies relying on global supply chains will see improved margins and increased access to goods.
Improving SBA Engagement on Employee Ownership Act
The 'Improving SBA Engagement on Employee Ownership Act' (HR5778) is active, having been placed on the Union Calendar on December 17, 2025. This bill mandates increased SBA outreach for Employee Stock Ownership Plans (ESOPs), creating a growth catalyst for financial institutions, consulting firms, and legal services specializing in ESOPs. Financial sector stocks like JPMorgan Chase & Co. ($JPM), Bank of America Corporation ($BAC), Wells Fargo & Company ($WFC), Morgan Stanley ($MS), and The Goldman Sachs Group, Inc. ($GS) have shown positive 7-day performance, while Accenture plc ($ACN) has seen a modest 7-day increase.
SUPPORT for Patients and Communities Reauthorization Act of 2025
The SUPPORT for Patients and Communities Reauthorization Act of 2025, now Public Law 119-44, reauthorizes federal funding for substance use disorder and mental health programs through FY2030. This legislation establishes a sustained revenue stream for healthcare providers, diagnostic companies, and pharmaceutical distributors by increasing demand for related services and products. Recent market data shows mixed performance among healthcare-related companies, with diagnostic companies $LH and $DGX showing positive 7-day changes, while distributors $MCK and $CAH experienced slight declines or modest gains.
ROBINHOOD Act
The ROBINHOOD Act, HR6438, introduces a 20% excise tax on secured loans and lines of credit for high-income individuals, directly impacting the profitability of financial institutions offering these products. This bill targets a specific revenue stream for major banks and wealth management firms. Its early stage in the House Committee on Ways and Means means no immediate market action, but it signals future headwinds for lenders to high-net-worth clients.
Stop Stealing our Chips Act
The Stop Stealing our Chips Act establishes a whistleblower program for export control violations related to advanced AI chips, increasing compliance costs for companies in sensitive technology sectors. This bill does not allocate new funding or create new restrictions, limiting its immediate market impact to operational adjustments. No direct financial gains or losses are immediately apparent for specific companies.
Affordable Housing Bond Enhancement Act
The Affordable Housing Bond Enhancement Act (S1511) is currently in the committee hearing/markup stage in the Senate. This bill aims to expand housing investment through mortgage revenue bonds, which could provide a tailwind for homebuilders and financial institutions involved in bond issuance. While the bill has a companion in the House, its impact is not yet reflected in the 30-day performance of homebuilders, which shows declines, or in financial institutions, which show mixed performance.
Merchant Banking Modernization Act
The Merchant Banking Modernization Act (HR5291) extends the holding period for merchant banking investments by financial holding companies from 10 to 15 years, directly increasing flexibility and potential returns for major financial institutions engaged in private equity. This regulatory change is progressing through the House, having been placed on the Union Calendar. Financial sector stocks, including $JPM, $GS, $MS, $BAC, and $WFC, have shown positive 7-day changes, indicating market optimism.
Live Charts
Other Filings by Jared Moskowitz
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.